Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Beyond the Biological Effect of a Chemically Characterized Poplar Propolis: Antibacterial and Antiviral Activity and Comparison with Flurbiprofen in Cytokines Release by LPS-Stimulated Human Mononuclear Cells.

Governa P, Cusi MG, Borgonetti V, Sforcin JM, Terrosi C, Baini G, Miraldi E, Biagi M.

Biomedicines. 2019 Sep 21;7(4). pii: E73. doi: 10.3390/biomedicines7040073.

2.

Myocarditis requiring extracorporeal membrane oxygenation support following Influenza B infection: a case report and literature review.

Marchetti L, Gandolfo C, Maglioni E, Contorni M, Arena F, Cusi MG.

New Microbiol. 2019 Jan;42(1):61-63. Epub 2019 Jan 21. Review.

3.

Non-granulomatous cerebellar infection by Acanthamoeba spp. in an immunocompetent host.

Modica S, Miracco C, Cusi MG, Tordini G, Muzii VF, Iacoangeli F, Nocentini C, Ali IKM, Roy S, Cerase A, Zanelli G, De Luca A, Montagnani F.

Infection. 2018 Dec;46(6):885-889. doi: 10.1007/s15010-018-1231-4. Epub 2018 Oct 4.

PMID:
30288678
4.

Brevibacterium casei bacteraemia in a port-a-cath carrier patient: a case report.

Magi B, Migliorini L, Sansoni A, Cusi MG.

Infez Med. 2018 Sep 1;26(3):263-265.

5.

Laboratory diagnosis of Mycoplasma pneumoniae infections: data analysis from clinical practice.

Montagnani F, Rossetti B, Vannoni A, Cusi MG, De Luca A.

New Microbiol. 2018 Jul;41(3):203-207. Epub 2018 Jun 6.

6.

Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine.

Correale P, Botta C, Staropoli N, Nardone V, Pastina P, Ulivieri C, Gandolfo C, Baldari TC, Lazzi S, Ciliberto D, Giannicola R, Fioravanti A, Giordano A, Zappavigna S, Caraglia M, Tassone P, Pirtoli L, Cusi MG, Tagliaferri P.

Oncotarget. 2018 Apr 17;9(29):20539-20554. doi: 10.18632/oncotarget.24993. eCollection 2018 Apr 17.

7.

Haemagglutinin-neuraminidase from HPIV3 mediates human NK regulation of T cell proliferation via NKp44 and NKp46.

McQuaid S, Loughran S, Power P, Maguire P, Walls D, Cusi MG, Orvell C, Johnson P.

J Gen Virol. 2018 Jun;99(6):763-767. doi: 10.1099/jgv.0.001070. Epub 2018 Apr 23. Erratum in: J Gen Virol. 2018 Sep;99(9):1344.

PMID:
29683419
8.

Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients.

Pastina P, Nardone V, Croci S, Battaglia G, Vanni F, Bellan C, Barbarino M, Ricci V, Costantini S, Capone F, Botta C, Zarone MR, Misso G, Boccellino M, Caraglia M, Giordano A, Paladini P, Tassone P, Tagliaferri P, Cusi MG, Pirtoli L, Correale P.

J Thorac Dis. 2017 Sep;9(9):3123-3131. doi: 10.21037/jtd.2017.08.68.

9.

Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev).

Pastina P, Nardone V, Botta C, Croci S, Tini P, Battaglia G, Ricci V, Cusi MG, Gandolfo C, Misso G, Zappavigna S, Caraglia M, Giordano A, Aldinucci D, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Oncotarget. 2017 Aug 24;8(44):75904-75913. doi: 10.18632/oncotarget.20411. eCollection 2017 Sep 29.

10.

Type I interferons induced by endogenous or exogenous viral infections promote metastasis and relapse of leishmaniasis.

Rossi M, Castiglioni P, Hartley MA, Eren RO, Prével F, Desponds C, Utzschneider DT, Zehn D, Cusi MG, Kuhlmann FM, Beverley SM, Ronet C, Fasel N.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4987-4992. doi: 10.1073/pnas.1621447114. Epub 2017 Apr 24.

11.

A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.

Wiegand MA, Gori-Savellini G, Gandolfo C, Papa G, Kaufmann C, Felder E, Ginori A, Disanto MG, Spina D, Cusi MG.

J Virol. 2017 Apr 28;91(10). pii: e02298-16. doi: 10.1128/JVI.02298-16. Print 2017 May 15.

12.

Non-HCV-related cryoglobulinemic vasculitis and parvovirus-B19 infection.

Lazzerini PE, Cusi MG, Selvi E, Capecchi M, Moscadelli V, Migliacci N, Finizola F, Laghi-Pasini F.

Joint Bone Spine. 2018 Jan;85(1):129-130. doi: 10.1016/j.jbspin.2016.12.013. Epub 2017 Jan 3. No abstract available.

PMID:
28062379
13.

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients.

Martino EC, Misso G, Pastina P, Costantini S, Vanni F, Gandolfo C, Botta C, Capone F, Lombardi A, Pirtoli L, Tassone P, Ulivieri C, Tagliaferri P, Cusi MG, Caraglia M, Correale P.

Cell Death Discov. 2016 Oct 3;2:16025. eCollection 2016.

14.

The route to solve the interplay between inflammation, angiogenesis and anti-cancer immune response.

Botta C, Misso G, Martino EC, Pirtoli L, Cusi MG, Tassone P, Tagliaferri P, Caraglia M, Correale P.

Cell Death Dis. 2016 Jul 21;7:e2299. doi: 10.1038/cddis.2016.211. No abstract available.

15.

Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Correale P, Botta C, Martino EC, Ulivieri C, Battaglia G, Carfagno T, Rossetti MG, Fioravanti A, Guidelli GM, Cheleschi S, Gandolfo C, Carbone F, Baldari TC, Tassone P, Tagliaferri P, Pirtoli L, Cusi MG.

Oncoimmunology. 2015 Dec 21;5(4):e1101205. eCollection 2016 Apr.

16.

Toscana virus infects dendritic and endothelial cells opening the way for the central nervous system.

Cusi MG, Gandolfo C, Terrosi C, Gori Savellini G, Belmonte G, Miracco C.

J Neurovirol. 2016 Jun;22(3):307-15. doi: 10.1007/s13365-015-0395-2. Epub 2015 Oct 28.

PMID:
26510872
17.

Truncation of the C-terminal region of Toscana Virus NSs protein is critical for interferon-β antagonism and protein stability.

Gori Savellini G, Gandolfo C, Cusi MG.

Virology. 2015 Dec;486:255-62. doi: 10.1016/j.virol.2015.09.021. Epub 2015 Oct 27.

18.

Virucidal activity of a novel non-alcoholic combination of disinfectants.

Cusi MG, Fanigliulo D.

J Chemother. 2016 Apr;28(2):140-2. doi: 10.1179/1973947815Y.0000000072. No abstract available.

PMID:
26404483
19.

Seroprevalence of hepatitis E virus (HEV) infection in blood donors and renal transplant recipients: a retrospective study from central Italy.

Puttini C, Riccio ML, Redi D, Tordini G, Cenerini M, Romanello F, De Luca A, Carmellini M, Fossombroni V, Cusi MG, Zanelli G.

Infez Med. 2015 Sep;23(3):253-6.

20.

Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients.

Cusi MG, Botta C, Pastina P, Rossetti MG, Dreassi E, Guidelli GM, Fioravanti A, Martino EC, Gandolfo C, Pagliuchi M, Basile A, Carbone SF, Ricci V, Micheli L, Tassone P, Tagliaferri P, Pirtoli L, Correale P.

Cancer Immunol Immunother. 2015 Sep;64(9):1159-73. doi: 10.1007/s00262-015-1711-7. Epub 2015 Jun 2.

PMID:
26031574
21.

Editorial overview: anti-infectives: towards novel antiviral and antibacterial drugs? Current approaches to address a growing medical need.

Docquier JD, Cusi MG.

Curr Opin Pharmacol. 2014 Oct;18:iv-vi. doi: 10.1016/j.coph.2014.10.004. Epub 2014 Oct 22. No abstract available.

PMID:
25454403
22.

Serological and molecular detection of Toscana and other Phleboviruses in patients and sandflies in Tunisia.

Fezaa O, M'ghirbi Y, Savellini GG, Ammari L, Hogga N, Triki H, Cusi MG, Bouattour A.

BMC Infect Dis. 2014 Nov 15;14:598. doi: 10.1186/s12879-014-0598-9.

23.

Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection.

Ambrosio MR, De Falco G, Gozzetti A, Rocca BJ, Amato T, Mourmouras V, Gazaneo S, Mundo L, Candi V, Piccaluga PP, Cusi MG, Leoncini L, Lazzi S.

Haematologica. 2014 Nov;99(11):e235-7. doi: 10.3324/haematol.2014.111872. Epub 2014 Sep 5. No abstract available.

24.

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.

Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P.

J Immunother. 2014 Jan;37(1):26-35. doi: 10.1097/CJI.0000000000000004.

PMID:
24316553
25.

HCMV infection in renal transplant recipients: a retrospective cohort study.

Puttini C, Carmellini M, Garosi G, Rossetti B, Riccio ML, Tordini G, Cusi MG, De Luca A, Zanelli G.

New Microbiol. 2013 Oct;36(4):363-71. Epub 2013 Oct 1.

26.

Evaluation of a novel immunogenic vaccine platform based on a genome replication-deficient Sendai vector.

Wiegand M, Gori-Savellini G, Martorelli B, Bossow S, Neubert WJ, Cusi MG.

Vaccine. 2013 Aug 20;31(37):3888-93. doi: 10.1016/j.vaccine.2013.06.053. Epub 2013 Jul 2.

PMID:
23831325
27.

Toscana virus NSs protein inhibits the induction of type I interferon by interacting with RIG-I.

Gori-Savellini G, Valentini M, Cusi MG.

J Virol. 2013 Jun;87(12):6660-7. doi: 10.1128/JVI.03129-12. Epub 2013 Apr 3.

28.

Seroprevalence of antibodies to sandfly fever Sicilian virus in a sample population in Tuscany, Italy.

Cusi MG, Gandolfo C, Valentini M, Savellini GG.

Vector Borne Zoonotic Dis. 2013 May;13(5):345-6. doi: 10.1089/vbz.2011.0945. Epub 2013 Jan 5.

PMID:
23289397
29.

Testicular involvement during Toscana virus infection: an unusual manifestation?

Zanelli G, Bianco C, Cusi MG.

Infection. 2013 Jun;41(3):735-6. doi: 10.1007/s15010-012-0368-9. Epub 2012 Nov 17. No abstract available.

PMID:
23160838
30.

Comparison of a new prototype immunochromatographic assay and a commercial enzyme-linked immunosorbent assay for the detection of serum antibodies against Toscana virus.

Houghton R, Gori Savellini G, Chen H, Stevens Y, Moon J, Morkowski S, Raychaudhuri S, Valentini M, Cusi MG.

J Virol Methods. 2013 Jan;187(1):182-4. doi: 10.1016/j.jviromet.2012.09.015. Epub 2012 Sep 25.

PMID:
23022418
31.

Immunoglobulin M seropositivity for Toscana virus in a random population sample in Sicily.

Amodio E, Cusi MG, Valenti RM, Valentini M, Mammina C, Gori-Savellini G, Vitale F, Romano N, Goedert JJ, Calamusa G.

Int J Infect Dis. 2012 Aug;16(8):e633-5. doi: 10.1016/j.ijid.2012.04.012. Epub 2012 Jun 21.

32.

EBV Reactivation and Chromosomal Polysomies: Euphorbia tirucalli as a Possible Cofactor in Endemic Burkitt Lymphoma.

Mannucci S, Luzzi A, Carugi A, Gozzetti A, Lazzi S, Malagnino V, Simmonds M, Cusi MG, Leoncini L, van den Bosch CA, De Falco G.

Adv Hematol. 2012;2012:149780. doi: 10.1155/2012/149780. Epub 2012 Apr 24.

33.

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

Botta C, Bestoso E, Apollinari S, Cusi MG, Pastina P, Abbruzzese A, Sperlongano P, Misso G, Caraglia M, Tassone P, Tagliaferri P, Correale P.

J Immunother. 2012 Jun;35(5):440-7. doi: 10.1097/CJI.0b013e31825943aa.

PMID:
22576349
34.

Seroprevalence of and risk factors for Toscana and Sicilian virus infection in a sample population of Sicily (Italy).

Calamusa G, Valenti RM, Vitale F, Mammina C, Romano N, Goedert JJ, Gori-Savellini G, Cusi MG, Amodio E.

J Infect. 2012 Feb;64(2):212-7. doi: 10.1016/j.jinf.2011.11.012. Epub 2011 Nov 18.

35.

Prevalence of toscana and sicilian phlebovirus antibodies in classic Kaposi sarcoma case patients and control subjects in sicily.

Amodio E, Valentini M, Gori-Savellini G, Valenti RM, Romano N, Goedert JJ, Cusi MG.

J Infect Dis. 2011 Nov;204(9):1423-6. doi: 10.1093/infdis/jir546. Epub 2011 Sep 7.

36.

Diagnostic tools for Toscana virus infection.

Cusi MG, Savellini GG.

Expert Rev Anti Infect Ther. 2011 Jul;9(7):799-805. doi: 10.1586/eri.11.54. Review.

PMID:
21810052
37.

Retrospective diagnosis of West Nile virus infection in a patient with meningoencephalitis in Tuscany, Italy.

Cusi MG, Roggi A, Terrosi C, Gori Savellini G, Toti M.

Vector Borne Zoonotic Dis. 2011 Nov;11(11):1511-2. doi: 10.1089/vbz.2010.0248. Epub 2011 Jul 14.

PMID:
21756029
38.

RSV and HMPV seroprevalence in Tuscany (Italy) and North-Rhine Westfalia (Germany) in the winter season 2009/2010.

Cusi MG, Terrosi C, Kleines M, Schildgen O.

Influenza Other Respir Viruses. 2011 Nov;5(6):380-1. doi: 10.1111/j.1750-2659.2011.00252.x. Epub 2011 Apr 18. No abstract available.

39.

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

Correale P, Botta C, Cusi MG, Del Vecchio MT, De Santi MM, Gori Savellini G, Bestoso E, Apollinari S, Mannucci S, Marra M, Abbruzzese A, Aquino A, Turriziani M, Bonmassar L, Caraglia M, Tagliaferri P.

Int J Cancer. 2012 Apr 1;130(7):1577-89. doi: 10.1002/ijc.26181. Epub 2011 Aug 16.

40.

Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm?

Correale P, Cusi MG, Tagliaferri P.

Immunotherapy. 2011 Jan;3(1):1-4. doi: 10.2217/imt.10.92. No abstract available.

41.

Histological description of the lymphadenopathy related to Toscana virus infection. Report of a case.

Ranaldi R, Goteri G, Biagetti S, Cusi MG, Rossini S.

Pathol Res Pract. 2011 Mar 15;207(3):197-201. doi: 10.1016/j.prp.2010.07.010. Epub 2010 Nov 5.

PMID:
21115298
42.

Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects.

Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P.

Immun Ageing. 2010 Oct 20;7:14. doi: 10.1186/1742-4933-7-14.

43.

Toscana virus induces interferon although its NSs protein reveals antagonistic activity.

Gori Savellini G, Weber F, Terrosi C, Habjan M, Martorelli B, Cusi MG.

J Gen Virol. 2011 Jan;92(Pt 1):71-9. doi: 10.1099/vir.0.025999-0. Epub 2010 Sep 22.

PMID:
20861320
44.

Why is influenza virus more risky for pregnant women?

Cusi MG.

Influenza Other Respir Viruses. 2010 Sep;4(5):247-8. doi: 10.1111/j.1750-2659.2010.00156.x. No abstract available.

45.

Editorial: arthropod-borne viruses and emergent viruses.

Cusi MG.

Open Virol J. 2010 Apr 22;4:7. doi: 10.2174/1874357901004020007. No abstract available.

46.

Toscana virus epidemiology: from Italy to beyond.

Cusi MG, Savellini GG, Zanelli G.

Open Virol J. 2010 Apr 22;4:22-8. doi: 10.2174/1874357901004020022.

47.

Serum antibody response to respiratory syncytial virus F and N proteins in two populations at high risk of infection: children and elderly.

Sastre P, Cusi MG, Manoha C, Schildgen O, Ruiz T, Vela C, Rueda P.

J Virol Methods. 2010 Sep;168(1-2):170-6. doi: 10.1016/j.jviromet.2010.05.011. Epub 2010 May 19.

PMID:
20488207
48.

Age-dependent seroprevalence of Toscana virus in central Italy and correlation with the clinical profile.

Terrosi C, Olivieri R, Bianco C, Cellesi C, Cusi MG.

Clin Vaccine Immunol. 2009 Aug;16(8):1251-2. doi: 10.1128/CVI.00376-08. Epub 2009 Jun 24.

49.

Bayesian skyline plot inference of the Toscana virus epidemic: a decline in the effective number of infections over the last 30 years.

Zehender G, Bernini F, Delogu M, Cusi MG, Rezza G, Galli M, Ciccozzi M.

Infect Genet Evol. 2009 Jul;9(4):562-6. doi: 10.1016/j.meegid.2009.02.007. Epub 2009 Feb 27.

PMID:
19460322
50.

Humoral immunity to respiratory syncytial virus in young and elderly adults.

Terrosi C, Di Genova G, Martorelli B, Valentini M, Cusi MG.

Epidemiol Infect. 2009 Dec;137(12):1684-6. doi: 10.1017/S0950268809002593. Epub 2009 Apr 15.

PMID:
19366492

Supplemental Content

Support Center